The cited paper was immediately followed in the same issue of Science by: John Misasi, Morgan A. Gilman, Masaru Kanekiyo et al, "Structural and molecular basis for Ebola virus neutralization by protective human antibodies," Science, 351, 1343-1346. This paper illustrates crystal structures at 2Å resolution of the Ebola viral epitopes that are being recognized and targeted by monoclonal antibodies from a particular human survivor of the 1995 Kikwit (Congo) Ebola outbreak, who happened to mount an unusual and very robust and potent immune response.

(Thanks to Juan Weiss for this reference and its interpretation.)

Order of authorship in the original publication: Mulangu, Dodd, Davey.... One synthetic drug (Remdesivir, an antiviral) and 3 biologicals were used in this trial. The 3 biologicals were: REGN-EB3, a triple monoclonal antibody biologic, and Mab114, a single monoclonal antibody biologic, and ZMapp, another triple monoclonal antibody biologic. REGN-EB3, and Mab114 outperformed the other two, reducing mortality from up to 90% in the untreated to 33.5% for the REGN group and 35.1% for the Mab114 group. This was the first randomized, controlled trial of biopharmaceuticals that had significant success in curing Ebola. Digital text from nejm.org at this link.

(Thanks to Juan Weiss for this reference and its interpretation.)